# OnCo record kaposi-sarcoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/kaposi-sarcoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "kaposi-sarcoma" ;
  schema:name "Kaposi sarcoma"@en ;
  schema:alternateName "KS"@en, "HHV-8-associated sarcoma"@en ;
  schema:description "Kaposi sarcoma is a blood-vessel cancer caused by the herpesvirus HHV-8, made famous by the AIDS epidemic. In people with HIV, antiretroviral therapy alone often shrinks it; liposomal doxorubicin or paclitaxel treat advanced disease, and it remains among the commonest cancers in sub-Saharan Africa, where paclitaxel is often unaffordable."@en ;
  schema:url <https://onco.cc/cancers/kaposi-sarcoma/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Kaposi%27s_sarcoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q725345> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1447>, <https://doi.org/10.1016/S0140-6736(19)33222-2>, <https://www.cancer.gov/types/soft-tissue-sarcoma/patient/kaposi-treatment-pdq> ;
  onco:tag "gap-fill", "skin", "viral", "global" ;
  onco:related <https://onco.cc/cancers/vascular-tumours/>, <https://onco.cc/cancers/angiosarcoma/>, <https://onco.cc/cancers/dermatofibrosarcoma-protuberans/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/global-oncology-access/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/pegylated-liposomal-doxorubicin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/pomalidomide/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/bleomycin/>, <https://onco.cc/drugs/everolimus/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/> ;
  onco:companies <https://onco.cc/companies/bms/>, <https://onco.cc/companies/johnson-johnson/> ;
  onco:pathways <https://onco.cc/pathways/vegf-angiogenesis/>, <https://onco.cc/pathways/pi3k-akt-mtor/> ;
  onco:terms <https://onco.cc/terms/irae/>, <https://onco.cc/terms/hhv8-kshv/> ;
  onco:journals <https://onco.cc/journals/tumour-virus-research/> ;
  onco:pipeline <https://onco.cc/drugs/pomalidomide/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/> ;
  onco:standardOfCare <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/pegylated-liposomal-doxorubicin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/pomalidomide/>, <https://onco.cc/drugs/pegylated-liposomal-doxorubicin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/pomalidomide/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/everolimus/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/bleomycin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/trials/actg-a5263/> .